Inhibition of human P-glycoprotein transport and substrate binding using a galantamine dimer

Hilda A. Namanja, Dana Emmert, Marcos M. Pires, Christine A. Hrycyna, Jean Chmielewski

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The human multidrug resistance transporter P-glycoprotein (P-gp) prevents the entry of compounds into the brain by an active efflux mechanism at the blood-brain barrier (BBB). Treatment of neurodegenerative diseases, therefore, has become a challenge and the development of new reversible inhibitors of P-gp is pertinent to overcome this problem. We report the design and synthesis of a crosslinked agent based on the Alzheimer's disease treatment galantamine (Gal-2) that inhibits P-gp-mediated efflux from cultured cells. Gal-2 was found to inhibit the efflux of the fluorescent P-gp substrate rhodamine 123 in cancer cells that over-express P-gp with an IC50 value of approximately 0.6 μM. In addition, Gal-2 was found to inhibit the efflux of therapeutic substrates of P-gp, such as doxorubicin, daunomycin and verapamil with IC50 values ranging from 0.3 to 1.6 μM. Through competition experiments, it was determined that Gal-2 modulates P-gp mediated efflux by competing for the substrate binding sites. These findings support a potential role of agents, such as Gal-2, as inhibitors of P-gp at the BBB to augment treatment of neurodegenerative diseases.

Original languageEnglish (US)
Pages (from-to)672-676
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume388
Issue number4
DOIs
StatePublished - Oct 30 2009
Externally publishedYes

Fingerprint

Galantamine
P-Glycoprotein
Dimers
Substrates
Neurodegenerative diseases
Blood-Brain Barrier
Neurodegenerative Diseases
Inhibitory Concentration 50
Rhodamine 123
Cells
Daunorubicin
Multiple Drug Resistance
Verapamil
Doxorubicin
Inhibition (Psychology)
Cultured Cells
Alzheimer Disease
Binding Sites
Brain

Keywords

  • ATP Binding Cassette transporter
  • Blood-brain barrier
  • Dimer
  • Galantamine
  • Inhibition
  • P-glycoprotein

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Inhibition of human P-glycoprotein transport and substrate binding using a galantamine dimer. / Namanja, Hilda A.; Emmert, Dana; Pires, Marcos M.; Hrycyna, Christine A.; Chmielewski, Jean.

In: Biochemical and Biophysical Research Communications, Vol. 388, No. 4, 30.10.2009, p. 672-676.

Research output: Contribution to journalArticle

Namanja, Hilda A. ; Emmert, Dana ; Pires, Marcos M. ; Hrycyna, Christine A. ; Chmielewski, Jean. / Inhibition of human P-glycoprotein transport and substrate binding using a galantamine dimer. In: Biochemical and Biophysical Research Communications. 2009 ; Vol. 388, No. 4. pp. 672-676.
@article{dc5d6237355b4dbfad411182b7f36859,
title = "Inhibition of human P-glycoprotein transport and substrate binding using a galantamine dimer",
abstract = "The human multidrug resistance transporter P-glycoprotein (P-gp) prevents the entry of compounds into the brain by an active efflux mechanism at the blood-brain barrier (BBB). Treatment of neurodegenerative diseases, therefore, has become a challenge and the development of new reversible inhibitors of P-gp is pertinent to overcome this problem. We report the design and synthesis of a crosslinked agent based on the Alzheimer's disease treatment galantamine (Gal-2) that inhibits P-gp-mediated efflux from cultured cells. Gal-2 was found to inhibit the efflux of the fluorescent P-gp substrate rhodamine 123 in cancer cells that over-express P-gp with an IC50 value of approximately 0.6 μM. In addition, Gal-2 was found to inhibit the efflux of therapeutic substrates of P-gp, such as doxorubicin, daunomycin and verapamil with IC50 values ranging from 0.3 to 1.6 μM. Through competition experiments, it was determined that Gal-2 modulates P-gp mediated efflux by competing for the substrate binding sites. These findings support a potential role of agents, such as Gal-2, as inhibitors of P-gp at the BBB to augment treatment of neurodegenerative diseases.",
keywords = "ATP Binding Cassette transporter, Blood-brain barrier, Dimer, Galantamine, Inhibition, P-glycoprotein",
author = "Namanja, {Hilda A.} and Dana Emmert and Pires, {Marcos M.} and Hrycyna, {Christine A.} and Jean Chmielewski",
year = "2009",
month = "10",
day = "30",
doi = "10.1016/j.bbrc.2009.08.056",
language = "English (US)",
volume = "388",
pages = "672--676",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Inhibition of human P-glycoprotein transport and substrate binding using a galantamine dimer

AU - Namanja, Hilda A.

AU - Emmert, Dana

AU - Pires, Marcos M.

AU - Hrycyna, Christine A.

AU - Chmielewski, Jean

PY - 2009/10/30

Y1 - 2009/10/30

N2 - The human multidrug resistance transporter P-glycoprotein (P-gp) prevents the entry of compounds into the brain by an active efflux mechanism at the blood-brain barrier (BBB). Treatment of neurodegenerative diseases, therefore, has become a challenge and the development of new reversible inhibitors of P-gp is pertinent to overcome this problem. We report the design and synthesis of a crosslinked agent based on the Alzheimer's disease treatment galantamine (Gal-2) that inhibits P-gp-mediated efflux from cultured cells. Gal-2 was found to inhibit the efflux of the fluorescent P-gp substrate rhodamine 123 in cancer cells that over-express P-gp with an IC50 value of approximately 0.6 μM. In addition, Gal-2 was found to inhibit the efflux of therapeutic substrates of P-gp, such as doxorubicin, daunomycin and verapamil with IC50 values ranging from 0.3 to 1.6 μM. Through competition experiments, it was determined that Gal-2 modulates P-gp mediated efflux by competing for the substrate binding sites. These findings support a potential role of agents, such as Gal-2, as inhibitors of P-gp at the BBB to augment treatment of neurodegenerative diseases.

AB - The human multidrug resistance transporter P-glycoprotein (P-gp) prevents the entry of compounds into the brain by an active efflux mechanism at the blood-brain barrier (BBB). Treatment of neurodegenerative diseases, therefore, has become a challenge and the development of new reversible inhibitors of P-gp is pertinent to overcome this problem. We report the design and synthesis of a crosslinked agent based on the Alzheimer's disease treatment galantamine (Gal-2) that inhibits P-gp-mediated efflux from cultured cells. Gal-2 was found to inhibit the efflux of the fluorescent P-gp substrate rhodamine 123 in cancer cells that over-express P-gp with an IC50 value of approximately 0.6 μM. In addition, Gal-2 was found to inhibit the efflux of therapeutic substrates of P-gp, such as doxorubicin, daunomycin and verapamil with IC50 values ranging from 0.3 to 1.6 μM. Through competition experiments, it was determined that Gal-2 modulates P-gp mediated efflux by competing for the substrate binding sites. These findings support a potential role of agents, such as Gal-2, as inhibitors of P-gp at the BBB to augment treatment of neurodegenerative diseases.

KW - ATP Binding Cassette transporter

KW - Blood-brain barrier

KW - Dimer

KW - Galantamine

KW - Inhibition

KW - P-glycoprotein

UR - http://www.scopus.com/inward/record.url?scp=69949156876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949156876&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2009.08.056

DO - 10.1016/j.bbrc.2009.08.056

M3 - Article

VL - 388

SP - 672

EP - 676

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 4

ER -